相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Advances in Targeting RET-Dependent Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2020)
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
V. A. Papadimitrakopoulou et al.
ANNALS OF ONCOLOGY (2020)
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
S. Novello et al.
ANNALS OF ONCOLOGY (2018)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neal I. Lindeman et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer
Keke Nie et al.
LUNG CANCER (2018)
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Y. -L. Wu et al.
ANNALS OF ONCOLOGY (2015)
Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses
Gideon M. Blumenthal et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Jean-Charles Soria et al.
LANCET ONCOLOGY (2015)
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
Peter M. Ellis et al.
LANCET ONCOLOGY (2014)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Biomarkers and surrogate end points-the challenge of statistical validation
Marc Buyse et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim et al.
LANCET (2008)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)